Fibromyalgia - Drug Pipeline Landscape, 2023

Fibromyalgia - Drug Pipeline Landscape, 2023

Fibromyalgia is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues.

Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD.

Fibromyalgia can be diagnosed if the patient had widespread pain for 3 months or longer. Healthcare professionals use a process of elimination to diagnose fibromyalgia, for concluding that no other condition is causing the pain. Healthcare professionals may rule out other conditions that may have similar symptoms with some tests including complete blood count, Rheumatoid factor, thyroid function tests, anti-nuclear antibody, cyclic citrullinated peptide test etc.

Treatment of fibromyalgia includes medications such as pain relievers, antidepressants and anti-seizure drugs. therapies like physical therapy, occupational therapy and counselling can also be advised.

There are many companies that are actively developing drugs for the treatment of fibromyalgia, including Pfizer, Astellas Pharma, Tonix Pharmaceuticals, Cortene Inc etc.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Fibromyalgia treatment such as Esreboxetine, TNX-102, ASP0819 and others. Key players involved in the development of therapies to treat Fibromyalgia are Aardvark Therapeutics Inc, Astellas Pharma Inc, Cortene Inc, Pfizer, Tonix Pharmaceuticals Inc and others. Two drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, IND/CTA Filed and Preclinical stages of development.

Report Highlights

Global Insight Service's, Fibromyalgia - Drug Pipeline Landscape, 2023 report provides an overview of the Fibromyalgia pipeline drugs. This report covers detailed insights on Fibromyalgia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Fibromyalgia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.